Quick Answer
In a Phase 1 single-dose study, Briere and colleagues reported an eloralintide (LY3841136) terminal half-life of approximately 310 to 366 hours (about 13 to 15 days) across studied doses. This describes a clinical research finding, not instructions for use. Eloralintide is investigational.
The study included 48 healthy participants. The authors reported 16 adverse events among nine participants in the eloralintide groups; 15 were mild, and one vomiting event was moderate. This small single-dose study cannot establish long-term safety. Lilly funded the research, and the authors disclosed that they were Lilly employees and shareholders. These findings describe the clinical study formulation and do not establish the properties of separately supplied research materials.
If there’s one number to remember from this article, it’s this:
In the Phase 1 study, the reported terminal half-life was approximately 13 to 15 days. Half-life describes a decline in concentration during the terminal elimination phase, not a fixed time before any decline begins.
Half-life is one part of the pharmacokinetic picture. Absorption, distribution and elimination also inform the design of clinical research. For another amylin analog, our petrelintide research update discusses its reported Phase 1 half-life. These are separate studies and do not establish comparative effectiveness or safety.
Research Snapshot
| Category | Information |
|---|---|
| Compound | Eloralintide (LY3841136) |
| Research Class | Long-acting amylin receptor agonist |
| Developer | Eli Lilly |
| Terminal Half-Life | 310-366 hours (13-15 days), in the Briere et al. Phase 1 study |
| Time to Peak (Tmax) | 72-132 hours, median across groups in the same Phase 1 study |
| Later Phase 2 schedule | Once-weekly dosing was studied in a separate 48-week Phase 2 trial; it was not the schedule of the single-dose Phase 1 study. |
| Current Status | Investigational compound |
The emergence of Eloralintide has generated significant interest throughout the obesity research community. As new data continue to be presented from clinical development programs, researchers are asking an important question:
What gives Eloralintide its long half-life, and why is it designed for once-weekly administration?
Understanding the answer requires looking beyond simple timelines. Half-life is one measure researchers use to describe exposure and inform clinical study design. It does not by itself establish how consistently receptors are engaged.
In this guide, we’ll explore the published pharmacokinetic data surrounding Eloralintide, explain what half-life actually means, discuss why Lilly designed the molecule the way it did, and compare its characteristics with several other well-known metabolic research peptides.
What Is Eloralintide?
Eloralintide is an investigational long-acting amylin receptor agonist currently being studied by Eli Lilly for obesity and metabolic disease research.
Unlike GLP-1 receptor agonists, Eloralintide targets the body’s amylin signaling pathway, which plays an important role in appetite regulation, feelings of fullness after meals, and gastric emptying.
Researchers are especially interested in Eloralintide because of its:
- Long duration of action
- Once-weekly study schedule
- Prolonged measured systemic exposure in the cited study
- Potential compatibility with GLP-1 based therapies
- Promising early weight management research
One characteristic helping separate Eloralintide from earlier amylin compounds is its unusually long pharmacokinetic profile.
What Does “Half-Life” Mean?
The terminal half-life is the time for the concentration in blood plasma to decrease by half during the terminal elimination phase. It is an estimate and can vary across populations and conditions.
A simple way to picture it: If a concentration is 100 units at a point in the terminal phase, an idealized constant half-life model would put it at 50 after one half-life and 25 after two. Real measurements vary, and this illustration does not predict an individual’s exposure or tell us how long an effect lasts.
A longer half-life generally means a compound remains available longer before being eliminated. This often allows researchers to evaluate less frequent administration schedules while maintaining relatively stable exposure levels.
Importantly, a long half-life does not necessarily mean stronger biological activity. Instead, it primarily describes how long the molecule remains available within the body.
What Is Eloralintide’s Half-Life?
Based on published clinical research, Eloralintide demonstrates a terminal half-life of approximately 13 to 15 days (roughly 310 to 366 hours).
Does a long half-life tell us how often a compound should be used? No. A terminal half-life describes the decline of measured drug exposure under the conditions of that study. It is not a laboratory-storage period, a dosing recommendation or proof of identical kinetics in every population. The single-dose Phase 1 findings should be read alongside the different, registered studies in the eloralintide clinical trial index. For material rather than human pharmacokinetics, see the separate research peptide storage guide.
This places Eloralintide among the longer-lasting investigational metabolic peptides currently under development.
Several pharmacokinetic observations have attracted attention:
- Slow absorption following administration
- Extended circulation time
- Sustained systemic exposure
- Gradual elimination over multiple days
These characteristics help explain why researchers selected a once-weekly administration schedule during clinical development rather than requiring more frequent administration.
Why Doesn’t Eloralintide Reach Peak Levels Immediately?
One interesting feature of Eloralintide is that maximum blood concentrations are not reached immediately after administration.
In the single-dose Phase 1 study reported by Briere and colleagues, median time to peak concentration ranged from about 72 to 132 hours across the studied amounts. This describes the study formulation and participants, not a prediction for a research material.
The measured absorption and elimination profile helps researchers characterize exposure in that study. It does not, by itself, establish receptor engagement or predict the size of concentration changes under other study conditions.
Why Was Eloralintide Designed for Once-Weekly Administration?
Developing a peptide that remains active for an extended period offers several advantages during clinical research.
A longer-lasting compound may help provide:
More Stable Drug Exposure
Longer half-life can contribute to sustained exposure, but the size of peak-to-trough changes depends on the studied regimen and other pharmacokinetic properties.
Exposure and Receptor Activity
A longer exposure profile may influence receptor activity, but blood concentration alone does not establish continuous receptor engagement.
What Half-Life Does and Does Not Establish
An extended terminal half-life can inform clinical study planning, but does not independently establish an appropriate study interval or predict the behavior of a separately supplied research material.
Peak-to-Trough Variation Depends on the Regimen
Many modern metabolic therapies are intentionally engineered to minimize large swings in concentration levels.
Collectively, these characteristics may contribute to more predictable pharmacokinetic behavior throughout a study.
How Long Does Eloralintide Remain in the Body?
A common misconception is that a compound disappears after one half-life.
In reality, elimination is gradual.
As a simplified illustration of a constant terminal elimination rate, measured from a point within that phase:
- During a consistent terminal elimination phase, plasma concentration falls to approximately half its value over one terminal half-life.
- Under the same simplified conditions, it falls to approximately one-quarter of that starting value after two terminal half-lives.
- Concentration continues to decline over subsequent half-lives.
This illustration describes a decline in plasma concentration, not a precise prediction of the amount remaining in the body. Actual profiles vary with absorption, distribution, sampling and the study conditions.
This gradual elimination helps support a weekly research schedule.
Pharmacokinetics: More Than Just Half-Life
Half-life represents only one part of pharmacokinetics.
Researchers also evaluate:
Absorption
How quickly the compound enters circulation after administration.
Distribution
How the compound moves throughout the body.
Metabolism
How enzymes gradually break down the peptide.
Elimination
How the remaining compound and its metabolites are ultimately cleared.
Together, these measurements provide researchers with a complete picture of how a molecule behaves following administration.
Why Pharmacokinetics Matter
Understanding pharmacokinetics helps researchers answer important questions such as:
- Which schedules should be investigated in controlled clinical studies?
- When are peak concentrations expected?
- How long is receptor activity likely to continue?
- How much accumulation occurs after repeated weekly administration?
- How should future clinical studies be designed?
These measurements form the foundation of dosing schedule selection during drug development.
How Does Eloralintide Compare With Other Metabolic Research Peptides?
Eloralintide, cagrilintide and petrelintide are different compounds studied in amylin-related research. The articles below compare their published research profiles; they should not be read as evidence that these compounds were tested head-to-head.
- Cagrilintide vs Eloralintide: Which Amylin Receptor Agonist Shows Stronger Research Results?
- Eloralintide vs Retatrutide: A Research Comparison
- Eloralintide + Tirzepatide: Everything We Know So Far
| Compound | Primary Target | Intended Study Schedule |
|---|---|---|
| Eloralintide | Amylin receptor | Weekly |
| Tirzepatide | GLP-1/GIP receptors | Weekly |
| Semaglutide | GLP-1 receptor | Weekly |
| Cagrilintide | Amylin receptor | Weekly |
Although these compounds may share similar administration schedules, they differ substantially in receptor selectivity, molecular design, pharmacology, and clinical objectives.
For that reason, weekly administration should not be interpreted as meaning the compounds behave identically.
Why Researchers Are Excited About Eloralintide
Interest surrounding Eloralintide extends beyond its half-life.
Current research is exploring its potential effects on:
- Appetite regulation
- Body weight
- Metabolic health
- Gastric emptying
- Combination strategies with GLP-1 therapies
Its extended pharmacokinetic profile makes it an especially attractive candidate for long-term investigation.
Frequently Asked Questions
What is Eloralintide’s half-life?
In a Phase 1 single-dose study by Briere and colleagues, the reported terminal half-life was approximately 310 to 366 hours, or about 13 to 15 days, across studied doses. The finding describes a clinical research result, not a use recommendation.
Why is Eloralintide administered once weekly?
The clinical development program studied a weekly schedule in light of the compound’s pharmacokinetic profile. Study schedules do not provide instructions for research materials.
Does Eloralintide reach peak levels immediately?
No. Published data indicate that peak concentrations generally occur several days after administration rather than within hours.
What is pharmacokinetics?
Pharmacokinetics is the study of how a compound is absorbed, distributed, metabolized, and eliminated after administration.
Does a longer half-life mean a stronger compound?
Not necessarily. Terminal half-life describes the rate at which measured plasma concentration falls during the terminal elimination phase. It does not establish potency, effectiveness or how long an effect lasts.
Why do researchers study half-life?
Half-life helps determine appropriate administration schedules, expected exposure, and the overall design of future clinical studies.
Final Thoughts
Eloralintide’s extended half-life is one of the defining characteristics separating it from many earlier metabolic research peptides.
The Phase 1 study reported gradual absorption and a long terminal half-life. These pharmacokinetic observations helped inform clinical research, but they do not establish continuous or prolonged receptor engagement on their own.
As additional clinical data become available, researchers will continue evaluating how these pharmacokinetic characteristics influence weight management, metabolic outcomes, and future combination strategies.
For scientists following next-generation obesity research, understanding Eloralintide’s half-life provides valuable insight into why this investigational peptide has become one of the most closely watched compounds currently in development.
About Eloralintide at Xcel Peptides
Eloralintide is available from Xcel Peptides as a lyophilized powder for laboratory research use only. Review the available sample-specific analytical records to understand the tests performed and their limits. See how we verify eloralintide, review our independent Janoshik testing analysis, or read the eloralintide research overview.
This article is for educational and informational purposes only. Eloralintide is an investigational medicine. Separately supplied Xcel reference materials are for in-vitro laboratory research only, are not sterile or for injection, and are not for human or veterinary use. Nothing here is medical advice or a usage recommendation. All pharmacokinetic figures are drawn from published preclinical and clinical research.
Sources: Bhattachar et al., Diabetes, Obesity and Metabolism (2026) Phase 1 proof of concept; Eloralintide discovery-to-clinical-proof-of-concept paper (ScienceDirect, 2025); American Diabetes Association abstract 882-P; Lilly Phase 2 data (The Lancet, 2025).